治疗免疫炎性疾病的肿瘤坏死因子-α拮抗剂相关的感染性并发症的研究进展  

Advancement on Infectious Complication Induced by Tumor Necrosis Factor-αAntagonists for the Treatment of Immunoinflammatory Disease

作　　者：孙莉莉[1] 张蕾[1] 邱美丽[2] SUN Li-li;ZHANG Lei;QIU Mei-li(Department of General Medicine,the People's Hospital of Linqu,Linqu 262600,China;Department of Pharmacy,the Yidu Central Hospital of Weifang,Qingzhou 262500,China)

机构地区：[1]临朐县人民医院全医学科,山东临胸262600 [2]潍坊市益都中心医院药剂科,山东青州262500

出　　处：《药物生物技术》2023年第6期657-660,共4页Pharmaceutical Biotechnology

摘　　要：虽然临床实践证实肿瘤坏死因子-α拮抗剂能使免疫性炎症疾病患者受益,但大大增加了感染的风险。文章概述了肿瘤坏死因子-α拮抗剂诱导的感染性并发症以及临床上的降低感染风险的应对措施,并建议重视筛查和管理结核杆菌感染和乙肝病毒感染。Although tumor necrosis factor-α(TNF-α)antagonists have been shown to benefit patients with immune inflammatory disease in clinical practice,but these patients are at high risk of infections.The infectious complications induced by TNF-α antagonists and the clinical measures to reduce the risk of infection were outline in this review.High attention should be paid to screening and management of mycobacterium tuberculosis and hepatitis B virus infection.

关 键 词：免疫炎症疾病 肿瘤坏死因子 细菌 真菌 病毒 感染 

分 类 号：R593[医药卫生—内科学]